Prescribing anti-clotting medications to adults younger than age 65 who have atrial fibrillation (AFib) but no other risk ...

The ASUNCTIS trial evaluated asunercept's safety and efficacy in COVID-19, showing trends toward faster recovery despite not ...

AFib is the most common type of irregular heart rhythm in the U.S., and blood thinners, also known as anti-clotting ...

Dr Reddy's Laboratories and FDC Ltd, are recalling generic medications in the US over manufacturing defects. According to the ...

Half of the study participants were randomly selected to receive 15 mg of rivaroxaban daily ... The participants had a low incidence of stroke, at less than 1 in 100 (0.8%) per year. There were no ...

In the first large trial of its kind, the anti-clotting medication rivaroxaban did not lower the risk of cognitive decline ...

Researchers have tested a novel therapeutic concept to treat virus-induced lung failure in patients with severe COVID-19 in a phase 2 clinical trial. The approach may also be applicable to other ...

The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...

Older adults whose cholesterol levels fluctuate from year to year may face an increased risk for dementia and cognitive ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.